Gemcitabine in solid tumors – present status and further development

Oncology Research and Treatment

Volumn 20, Issue 4, 1997, Pages 297-304

  Arning, M ^a   Blatter, J ^a  

^a LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

Gemcitabine; Non small cell lung cancer; Pancreatic cancer

Indexed keywords

CISPLATIN; DEXAMETHASONE; GEMCITABINE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG METABOLISM; DRUG RESEARCH; DRUG TOLERABILITY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; METASTASIS; NEUTROPENIA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA;

EID: 0030832075     PISSN: 22965270     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218959     Document Type: Article

References (45)

1. Huang P, Chubb S, Hertel LW, Grindey G, Plunkcll W: Action of gemritabin on DNA synthesis. Cancer Res 1991:51:6110-6117.
2. Plunkett W, Huang P, Searcy CE. Gandhi V. Gemcitabine G: Pharmacology and mechanisms of action. Sent Oncol 1996:23, S10:3-15.
3. Heinemann V, Llertel LW, Grindey GB, Plunkett W: Comparison of the cellular pharmacokinetics and toxicity of 2'.2'-defluorodeoxycytidine and 1-ß-D-arabinofuranosyl-cylosine. Cancer Res 1988:48: 4024-4031.
4. Bouffard DY, Momparler RL: Comparison of the induction of apoptosis in human leukemic cell lines by 2'.2'-Difluorodeoxycytidine (geincitabine) and cytosine arabinoside. Leuk Res 1993; 11:849-856.
5. SAbbruzzese JL, Grünewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mlnelshi S, Tarassoff P, Satterlee W, Raber MN, Plunkett W: A phase I clinical. plasma, and cellular pharmacology study of geincitabine. J Clin Oncol 1991;9:491-498.
6. Allerheiligen S, Johnson R, Hatcher B: Gemcitabine pharmacokinetics are influenced by gender, body surface area (BSA). and duration of infusion. Proc ASCO 1994:13.
7. Ruizvan Haperen VWT, Vcerman G, Boven E, Noordhuis P, Vcrmorken JB, Peters GJ: Schedule dependence of sensitivity to 2\2'-difluorodeoxycyti-dine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. Biochem Pharmacol 1994: 48:1327-1339.
8. Ahlgrcn JD: Chemotherapy for pancreatic carcinoma. Cancer 1996;7853:654-663.
9. Casper ES, Green MR. Kelsen DP, Heelan RT, Brown TD. Flombaum CD. Trochanowski B. Tarassoff PG: Phase II trial of gemcltabine in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994;12:29-34.
10. O’Shaughnessy JA, Wittes RE, Burke G, Friedmann MA, Johnson JR, Niederhuber JE, Rothenberg ML, Woodcock J, Chabner BA, Temple R: Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials J Clin Oncol 1991;9:2225-2232.
11. Andersen IS, Burris HA, Casper E, dayman M, Green M, Nelson RL, Portenoy R, Rothenberg M, Tarassoff PG, von Hoff DD: Development of a new system for assessing clinical benefit for patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 1994:13:461.
12. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris III HA, Green MR, Tarassoff PG, Brown ID, Casper ES. Storniolo AM. von Hoff DD: A phase II trial of geincitabine in patients with 5-FLI-refractory pancreas cancer. Ann Oncol 1996:7:347-353.
13. Moore M, Andersen J, Burris H, Tarassoff P, Green M, Casper E, Portenoy R, Modiano M, Cripps C, Nelson R, Storniolo A, von Hoff D: A randomized trial of geincitabine versus 5-FU as first-line therapy in advanced pancreatic cancer. Proc ASCO 1995: 14:199.
14. Carmichael J, Fink U, Russell RCG, Spittle MF, Harris A. Spiessi G. Blatter J: Phase II study of gem-citabinc in patients with advanced pancreatic cancer. Br J Cancer 1995:73:101-105.
15. Verwcij J: The benefit of clinical response: An European perspective. Ann Oncol 1996:7:333-334.
16. Gelber RD: Gemcitabine for pancreatic cancer: How hard to look for clinical benefit? Ann Oncol 1996:7:335-337.
17. Heinemann V, Wilke H, Posslnger K, Mergcnthaler K, Clemens M, König HJ, Illiger HJ, Blatter J, Schallhorn A, Fmk U: Gemcitabine and cisplatin: combination treatment for advanced and metastatic pancreatic carcinoma. Proc ASCO 1996:246.
18. Non Small Cell Lung Cancer Collaborative Group: Chemotherapy in NSCLC: A meta analysis using updated data on individual patients from 52 randomized trials. BMJ 1995:311:899-909.
19. Le Chevalier T: Single-agent activity of geincitabine in advanced Non-small cell lung cancer. Sent Oncol 23:5:36-42.
20. Thatcher N, Andersen H, Betticher DC, Ranson M; Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumor-related symptoms. Anti Cancer Drugs 1995;S6:40-48.
21. Manegold Ch, von Pawel J, Conte PE, Dornhoff W, van Walree NC, ten Bokkel Huinink WW, Drings P for the randomised trial group: Randomised phase II study of gemcitabine versus Cisplatin/Etoposide in patients with advanced non-small cell lung cancer (NSCLC) Ann Oncol 7:S5:3.
22. Peters GHQ, Bergman AM, Ruin van Haperen VWT: Interaction between cisplatin and gemcitabin in vitro and in vivo. Sem Oncol 1995:22.S 1:72-79.
23. Steward WP, Dunlop DJ, Cameron C, Talbot DC, Kleisbauer JP, Thomas P, Guerin JC, Perol M, Sanson C, Dabouis G, Lacroix H: Gemcitabine combined with cisplatin in non-small cell lung cancer: A phase II study. Eur J Cancer 1995:31A:5225.
24. Crinó L, Scaglioni G, Managolo M, Figoli F, Clerici M, De Marinis F, Salvati F, Cruciani G, Dogliotti L, Cocconi G, Paccagnella A, Adamo V, Incoronato P, Scarcella L, Mosconi AM, Tonato M: Gemcitabine cisplatin combination in non-small cell lung cancer. A phase II study. Eur J Cancer 1995-31A:S222.
25. Sandler A, Ansari R, McClean J, Fisher W, Dorr FA, Einhorn LH: Gemcitabine plus cisplatin in non-small cell lung cancer. A phase II study. Eur J Cancer 1995:31A:S225.
26. Abratl RP, Bezwoda WR, Goedhals L, Hacking DJ: Gemcitabine and cisplatin for advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1956: 15:381.
27. Shepherd F, Cormier Y, Evans W, Burkes R, Goss G, Klimo P. Feld R. Binder Iglesias J: A phase II study of gemcitabine and cisplatin weekly x 3 every 4 weeks in patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 1996:15:380.
28. Antón A, Carrato A, González Larriba JL, Vadell C, Masutti B, Montalar J, Aranda E. Barnetto J. Tarazona Y. López Martin E: Phase II activity of gemcitabine in combination with cisplatin in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1996:15:380.
29. Manegold CH, Eberhard W, Wilke H, Gatzemeier U, Chrorny F, Chronty P, Khayat D. Blatter J, Drings P: Phase II study of gemcitabine and ifosfamidc in advanced non-small cell lung cancer. Proc ASCO 1996:380.
30. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, Harris AL: Advanced breast cancer: a phase II trial with gemcitabine. J C'lin Oncol 1995:13:2731-2736.
31. Blackstein M, Vogel CL, Ambinder R, Cowan J, Pearce P, Iglesias J, Dorr FA: Phase II study of gemcitabine in patients with metastatic disease. Proc ASCO 1996:117.
32. Spielmann M, Pouillart P, Espió M, Llontbart-Cussac A, Namer M, Kalla S, Ferrerò JM, Cuvier C, Fumoleau P, Ponzio A. Kavaitalire L: Activity of gemcitabine in metastatic breast cancer patients previously treated with anthracyclinc-containing regimens. Ann Oncol 1996:7:S5.23.
33. Ltiftner D, Grünewald R, Flath B, Akrivakis C, Mergenthaler HG: Gemcitabine with dose escalated epirubicin in advanced breast cancer. Results of a phase I study. Ann Oncol 1996:7:17.
34. Connor JP, Olsson CA, Benson MC, Rapoport F, Sawczuk IS: Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of the urinary bladder: cause for concern. Urology 1989:34:353-356.
35. Pollera CF, Ceribelli A, Crccco M, Calabresi F: Weekly gemcitabine in advanced bladder cancer: A preliminary report from a phase I study. Ann Oncol 1994:5:182-184.
36. De Lena M, Lorusso V, Amadori D, Antinii M, Gridelli G, Luporini G, Pollera C, Oliva C: Gemcitabin in resistant stage IV bladder cancer. A phase II study. Eur J Cancer I995;31A:241.
37. Lund B, Hansen OP, Neijt JP, TTieilade K, Hansen M: Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients. J Natl Cancer Inst 1994:86:1531-1533.
38. Neijt JP, Kaufmann M, Bauknecht T, van Belle S, Jonat W, Piccart MJ, Thomas J, Wils MA, Nooy JAMJ, Grul CM: Gemcitabine in pre-treated ovarian cancer. Ann Oncol 1996;7:S5.70.
39. Gore ME, Levy V, Rustin G, Perren T, Calvert AH, Earl H, Thompson JM: Paclitaxel (taxol) in relapsed and refractory ovarian cancer. Br J Cancer 1995:72: 1016-1019.
40. Underhill C, Parnis FX, Highley M, Ahem J, Lund B, Kamby C. Carmichael J. Harper P. Williams C. Hirsch F. Hansen M, Smith G Walling J: A phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer. Ann Oncol 1996;785.69.
41. Green MR: Gemcitabine safety overview. Sent Oncol 1996;23.S5.32-35.
42. Iglcsias JL, Hatty S: Pulmonary safety of gemcitabine (Gemzar), Ann Oncol 1996:7(suppl 5):129-130.
43. Pavlakis N, Levi JA, Wheeler HR, Begbic SD, Bell DR: Novel pulmonary and neurological (CNS) toxi-citieswilh gemcitabine. Proc ASCO 1996; 181.
44. Shewach D, Lawrence TS: Radiosensitation of human solid tumor cell lines with gemcitabine. Sent Oncol 1996;23(suppl 5):65-71.
45. Catimcl G, Vermorken JB, Clavel M, de Mulder P, Judson I, Sessa C, Piccart M, Bruntsch U, Verweij J, Wanders J, Franklin H, Kaye SB: A phase II study of gemcitabine in patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994;5:543-547.